Delivery Order SPE2DB24D2105-SPE2DB25FAPNH
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections, with a contract ceiling value of $5,144.31. This is a firm fixed-price delivery order with an ultimate completion date of August 28, 2025, and represents a non-set-aside, competitively awarded procurement. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injections. This firm fixed-price delivery order, valued at $10,832.22, represents a competitive award with no set-aside designation and is scheduled for completion by June 3, 2025. The order will be fulfilled from AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania, the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections, with a contract ceiling value of $20,970.95. This is a firm fixed price delivery order with an ultimate completion date of September 16, 2025, and represents a non-competitive set-aside award. The order will be fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Zepbound (semaglutide) 2.5 mg/0.5 mL pen injections with a ceiling value of $6,055.29. This competitively awarded, firm fixed-price delivery order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 5, 2025. The contract carries no set-aside designation, reflecting...
- The Defense Logistics Agency awarded a $6,987.59 delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 ml pen injections. This is a firm fixed-price contract with an ultimate completion date of September 16, 2025, and represents a non-set-aside award issued through open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order valued at $7,848.75 to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Zepbound (semaglutide) 2.5 mg/0.5 mL pen injectors. This competitive, firm fixed-price delivery order is scheduled for completion by August 21, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a single transaction under the company's larger pharmaceutical supply framework with the federal...
- The Defense Logistics Agency awarded a $19,343.26 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pens. This competitively awarded, firm fixed-price contract is classified as a non-set-aside procurement and requires completion by July 25, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 2, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injections, with a ceiling value of $14,655.60 and a completion date of May 5, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injections with a ceiling value of $1,797.29. This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procedures and scheduled for completion by September 9, 2025. AmerisourceBergen Drug Corp will perform this work at its corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $5,919.38 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injections on September 19, 2025, with an ultimate completion date of September 22, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical...
- SPE2DB24D2105Indefinite Delivery Contract
- SPE2DB24D2105-SPE2DB25FAPNHDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 25, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 ml pen injections with a ceiling value of $1,949.95. This is a firm fixed price delivery order with an ultimate completion date of April 28, 2025, and represents a non-competitive set-aside contract. The order will be fulfilled from AmerisourceBergen's facility located in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. As a pharmaceutical prime vendor for the DLA Medical Supply Chain, AmerisourceBergen supplies a comprehensive range of medications and medical products to support military and federal healthcare systems globally, including the Defense Health Agency and U.S. Coast Guard. The company's position as a critical supplier within the federal pharmaceutical procurement structure reflects its demonstrated capability to meet ongoing defense medical supply requirements across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 4/25/25 |